New hope for Tough-to-Treat prostate cancer: first human trial begins
Disease control
Recruiting now
This is the first study in people to test a new drug called ACE-232 for men with metastatic prostate cancer that has stopped responding to standard hormone therapy. The main goal is to find a safe dose and see how the body handles the drug. Researchers will also look for early si…
Phase: PHASE1 • Sponsor: Acerand Therapeutics (Hong Kong) Limited • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC